Hospital Infection Therapeutics Market Value | Size,Trends,Forecast|

Data Bridge Market Research analyses that the hospital infection therapeutics market, which was USD 11.59 billion in 2022, is expected to reach USD 15.26 billion by 2030, at a CAGR of 3.5% during the forecast period 2023 to 2030. 

"To win the competition in the global market, choosing a reliable Hospital Infection Therapeutics Market  research report is very important. Businesses can gain insight into a complete industry background analysis that includes home market assessment. This market report takes into account the various market analysis segments demanded by today's businesses. Clients are used to a great combination of the best industry insights, practical solutions, talent solutions and the latest technology when using Hospital Infection Therapeutics Market reports for business growth. Market drivers and restraints have been explained here using SWOT analysis.

The key areas covered in the best Hospital Infection Therapeutics Market report include market definition, market segmentation, competitive analysis, and research methodology. Additionally, to better understand facts and figures, data is presented in the form of graphs, tables, and charts. This market research report is the definitive solution to have exclusive market research data that anticipates business needs. Apart from that, business people can find out the extent of market problems, the reasons for the failure of certain products already on the market, and the market prospects for new products that will be launched.

Data Bridge Market Research analyses that the hospital infection therapeutics market, which was USD 11.59 billion in 2022, is expected to reach USD 15.26 billion by 2030, at a CAGR of 3.5% during the forecast period 2023 to 2030. 

Explore Further Details about This Research Hospital Infection Therapeutics Market Report https://www.databridgemarketresearch.com/reports/global-hospital-infection-therapeutics-market

Hospital Infection Therapeutics Market Scope and Segmentation  

REPORT METRIC

DETAILS

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Therapeutics (Anti-Bacterial Drugs, Anti-Fungal Drugs, Anti-Viral Drugs, Others), Infections (Hospital Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections, Other Hospital Infections)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Merck Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc. (U.K.), AstraZeneca (U.K.), Johnson Johnson Services, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), AbbVie Inc. (U.S.), Sanofi (France), Gilead Sciences, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Basilea Pharmaceutica Ltd. (Switzerland), Spero Therapeutics (U.S.), BioSpace (Canada), POLYPID (Israel), Novartis AG (Switzerland), Bellerophon Therapeutics (U.S.),  Achilles Therapeutics plc. (U.K.)

Market Opportunities

  • Rising prevalence of infections
  • Rising RD initiatives

Market Definition

Hospital infection therapeutics refers to pharmaceutical drugs used to treat hospital nosocomial infections. These infections can occur in hospitals, nursing homes, rehabilitation centers, and other clinical settings and are typically treated with antiviral, antibacterial, and antifungal medications. Vancomycin, carbapenems, cephalosporins, linezolid, aminoglycosides, and tigecycline are antibacterial therapeutics inhibiting cell wall synthesis and protein synthesis. Caspofungin and Amphotericin B are antifungal therapeutics that help to prevent hospital-acquired pneumonia, urinary tract infections (UTIs), bloodstream infections, and surgical site infections.

Global Hospital Infection Therapeutics Market Dynamics

Drivers

  • Rising prevalence of hospital-acquired diseases

One of the key factors driving the market growth is the rising prevalence of hospital-acquired diseases (HAD). Furthermore, the growing geriatric population, which is more susceptible to such ailments, is driving market expansion. As a result of the deterioration of hygiene facilities in hospitals and other healthcare institutions, hospital-acquired pneumonia and other infections have increased significantly, contributing to the rising demand for hospital infection therapeutics.

  • Rising prevalence of infections

According to data published by the New York State Department of Health in November 2019, approximately 160 New York hospitals reported 1,139 colon SSIs out of 19,732 procedures in 2018, resulting in a rate of 5.8 infections per 100 procedures. According to the same source, approximately 15,310 cases of clostridioides difficile infections (CDI) were reported in acute care hospitals in New York in 2018. The high prevalence of hospital-acquired infections is expected to significantly increase the demand for treatment therapies and support the market growth during the forecast period.

Opportunities

  • Rising RD initiatives

The key market players are engaged in extensive RD initiatives for the development and indication expansion of their already approved HAI treatments. For instance, the FDA approved Allergan plc's supplemental New Drug Application (sNDA) in February 2018, expanding the approval of Avycaz (ceftazidime and avibactam) to include the treatment of HABP/VABP and hospital-acquired bacterial pneumonia.

Key Offerings:

  • Past Market Size and Competitive Landscape (2018 to 2022)
  • Past Pricing and price curve by region (2018 to 2022)
  • Market Size, Share, Size Forecast by different segment | 2023−2029
  • Hospital Infection Therapeutics Market Dynamics – Growth Drivers, Restraints, Opportunities, and Key Trends by Region
  • Market Segmentation – A detailed analysis by segment with their sub-segments and Region
  • Competitive Landscape – Profiles of selected key players by region from a strategic perspective
  • Competitive landscape – Market Leaders, Market Followers, Regional player
  • Competitive benchmarking of key players by region
  • PESTLE Analysis
  • PORTER’s analysis
  • Value chain and supply chain analysis
  • Legal Aspects of Business by Region
  • Lucrative business opportunities with SWOT analysis
  • Recommendations

Browse Related Reports:

Special Mission Aircraft  Market Size, Share Trends: Report

Foundry Chemicals  Market Size, Share, Industry, Forecast

Industrial Nailer  Market Size, Share Trends [Report]

Aviation Blockchain  Market Share Statistics Report,Size, Forecast, Trends

Ambient Assisted Living and Smart Home  Market Size, Global Industry Share, Recent

Photodiode Sensors  Market by Size, Share, Forecasts, Trends

Plant-based Yogurt Ingredients  Market Size | Statistics Report, Share, Forecast, Trends

About Data Bridge Market Research:

 US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email – corporatesales@databridgemarketresearch.com

"


Preksha

207 Blog posts

Comments